<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80287">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02060188</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-142</org_study_id>
    <secondary_id>2013-003939-30</secondary_id>
    <nct_id>NCT02060188</nct_id>
  </id_info>
  <brief_title>An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread</brief_title>
  <acronym>CheckMate142</acronym>
  <official_title>A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite High (MSI-H) and Non-MSI-H Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination
      with other anti-cancer drugs, will result in meaningful tumor size reduction, in patients
      with colon cancer that has come back or has spread, and who have a specific biomarker in
      their tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allocation: The Microsatellite Instability High (MSI-High) and C4 Cohort Parts of the trial
      are Non-randomized, The Non-MSI high Dose Escalation Phase part of the trial contained a
      randomized portion
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) in all MSI-High and non-MSI-High subjects as determined by Investigators</measure>
    <time_frame>The final analysis of the primary endpoint will occur at least 6 months after the last enrolled subject's first dose of study therapy (Approximately up to 34 months)</time_frame>
    <description>(Tumor imaging assessments will occur every 6 weeks from the date of first dose (+/-1 wk) for the first 24 weeks, then every 12 wks (+/- 1 wk) thereafter until disease progression or treatment is discontinued (whichever occurs later)) (Tumor imaging assessments will occur every 6 weeks from the date of first dose (+/-1 wk) for the first 24 weeks, then every 12 wks (+/- 1 wk) thereafter until disease progression or treatment is discontinued (whichever occurs later))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR in all MSI-H and non-MSI-H subjects based on IRRC determination</measure>
    <time_frame>The final analysis of the secondary endpoint will occur the time of the primary endpoint analysis (Approximately up to 34 months)</time_frame>
    <description>Tumor imaging assessments will occur every 6 weeks from the date of first dose (+/- wk) for the first 24 weeks, then every 12 wks (+/- 1 wk) thereafter until disease progression or treatment is discontinued(whichever occurs later)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>MSI Positive Colorectal Cancer</condition>
  <condition>MSI Negative Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Nivolumab Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab administered as IV infusion at a dose of 3mg/kg every 2 weeks until disease progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab (Nivo) + Ipilimumab (Ipi)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivo 3mg/Kg IV with Ipi 1 mg/Kg IV every 3 week (wk) for 4 doses followed by Nivo 3mg/Kg IV every 2wk until progression
Dose Escalation Phase: (Complete)
Dose Level (DL) 1: Nivo 0.3mg/Kg with Ipi 1 mg/Kg IV every 3wk for 4 doses followed by Nivo 3mg/Kg IV every 2wk until progression
DL 1: Nivo 1mg/Kg IV with Ipi 1 mg/Kg IV every 3 wk for 4 doses followed by Nivo 3mg/Kg IV every 2wk until progression
DL 2a: Nivo 1mg/Kg IV with Ipi 3 mg/Kg IV every 3wk for 4 doses followed by Nivo 3mg/Kg IV every 2 wk until progression
DL 2b: Nivo 3mg/Kg IV with Ipi 1 mg/Kg IV every 3wk for 4 doses followed by Nivo 3mg/Kg IV every 2 wk until progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab (Nivo) + Ipilimumab (Ipi) Cohort C3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivo IV dosed every 2wk with Ipi IV dosed every 6wk.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab (Nivo) + Ipilimumab (Ipi) + Cobimetinib Cohort C4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivo IV dosed every 2wk, with Ipi IV dosed every 6wk, combined with Cobimetinib dosed orally once daily 21 days on/7 days off.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab (Nivo) + BMS-986016 Cohort C5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivo IV dosed every 2wk with BMS-986016 dosed every 2 wk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab (Nivo) + Daratumumab Cohort C6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab IV dosed weekly for week 1-8; then every 2 wks from Week 9-24; then every 4 wks on week 25; with Nivo dosed every 2 wks starting at week 3 and every 4 wks starting at week 25</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <arm_group_label>Nivolumab (Nivo) + Ipilimumab (Ipi)</arm_group_label>
    <arm_group_label>Nivolumab (Nivo) + Ipilimumab (Ipi) Cohort C3</arm_group_label>
    <arm_group_label>Nivolumab (Nivo) + Ipilimumab (Ipi) + Cobimetinib Cohort C4</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Nivolumab Monotherapy</arm_group_label>
    <arm_group_label>Nivolumab (Nivo) + Ipilimumab (Ipi)</arm_group_label>
    <arm_group_label>Nivolumab (Nivo) + Ipilimumab (Ipi) Cohort C3</arm_group_label>
    <arm_group_label>Nivolumab (Nivo) + Ipilimumab (Ipi) + Cobimetinib Cohort C4</arm_group_label>
    <arm_group_label>Nivolumab (Nivo) + BMS-986016 Cohort C5</arm_group_label>
    <arm_group_label>Nivolumab (Nivo) + Daratumumab Cohort C6</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <arm_group_label>Nivolumab (Nivo) + Ipilimumab (Ipi) + Cobimetinib Cohort C4</arm_group_label>
    <other_name>Cotellic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <arm_group_label>Nivolumab (Nivo) + Daratumumab Cohort C6</arm_group_label>
    <other_name>Darzalex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-LAG-3 antibody</intervention_name>
    <arm_group_label>Nivolumab (Nivo) + BMS-986016 Cohort C5</arm_group_label>
    <other_name>BMS-986016</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Men and women â‰¥ 18 years of age

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1

          -  Histologically confirmed recurrent or metastatic colorectal cancer

          -  Measurable disease by CT or MRI

          -  Testing for MSI Status (by an accredited lab)

               1. Subjects with microsatellite instability high (MSI-H) tumors will enroll in the
                  MSI-H Cohort (mStage and cStage groups), the C3 Cohort, and the C5 Cohort.

               2. Subjects with phenotypes that are non-microsatellite instability high
                  (non-MSI-H) will enroll in the non- MSI-H Safety Cohort and the C6 Cohort.

          -  Adequate organ function as defined by study-specific laboratory tests

          -  Must use acceptable form of birth control throughout the study. After the final dose
             of study drug, an acceptable form of birth control must be used for 23 weeks for
             women of childbearing potential (WOCBP) and 31 weeks for men who are sexually active
             with WOCBP

          -  Signed informed consent

          -  Willing and able to comply with study procedures

          -  Subjects enrolled into the C3 Cohort must have not had treatment for their metastatic
             disease

        Exclusion Criteria:

          -  Active brain metastases or leptomeningeal metastases are not allowed.

          -  Prior treatment with an anti-Programmed Death Receptor (PD)-1, anti-PD-L1,
             anti-PD-L2, anti-Cytotoxic T-Cell Lymphoma-4 Antigen (CTLA-4) antibody, or any other
             antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint
             pathways

          -  Prior malignancy active within the previous 3 years except for locally curable
             cancers

          -  Subjects with active, known or suspected autoimmune disease

          -  Subjects with a condition requiring systemic treatment with either corticosteroids or
             other immunosuppressive medications within 14 days of study drug administration

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner Md Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomislav Dragovich, Site 0028</last_name>
      <phone>480-256-3429</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Usc Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinz-Josef Lenz, Site 0004</last_name>
      <phone>323-865-0820</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pacific Hematology Oncology Associates</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari Baron, Site 0001</last_name>
      <phone>415-600-1775</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bassel El-Rayes, Site 0008</last_name>
      <phone>404-778-1900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Clark, Site 0002</last_name>
      <phone>617-724-9347</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Clark, Site 0036</last_name>
      <phone>617-632-5960</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allina Health</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samith Kochuparambil, Site 0034</last_name>
      <phone>612-863-5658</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Morse, Site 0024</last_name>
      <phone>919-668-1861</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novant Health Oncology Specialists</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franklin Chen, Site 0029</last_name>
      <phone>336-718-8461</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center Oncology And Hematology Care- Eastside</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Crocenzi, Site 0005</last_name>
      <phone>503-215-2855</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Usman Shah, Site 0041</last_name>
      <phone>610-402-9543</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Upmc Cancer Pavilion</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Lee, Site 0013</last_name>
      <phone>412-623-2677</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Ctr</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Chan, Site 0006</last_name>
      <phone>615-936-5847</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University Of Texas Md Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Overman, Site 0003</last_name>
      <phone>713-563-7757</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0040</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tasman Oncology Research Pty Ltd</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Hill, Site 0039</last_name>
      <phone>+61411518959</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0037</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0019</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0018</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0020</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Sawyer, Site 0027</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albiruni Razak, Site 0016</last_name>
      <phone>416-946-4501</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0025</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dublin 4</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0022</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dublin 9</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0023</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0033</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Candiolo</city>
        <state>TO</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0030</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0035</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Padova</city>
        <zip>Padova</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0032</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0012</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0010</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0011</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>December 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
